Division of Endocrinology, Diabetes, and Metabolism, University Hospital Basel, Basel, Switzerland.
Pathology, Institute of Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.
Acta Cytol. 2022;66(5):371-378. doi: 10.1159/000522662. Epub 2022 May 5.
Fine-needle aspiration (FNA) is well-established for the evaluation of suspicious thyroid nodules. However, a significant proportion is nondiagnostic. Rapid on-site evaluation (ROSE) has been proposed to improve the overall adequacy of FNA.
Retrospective cohort study comparing adequacy of thyroid FNA findings pre- and postimplementation of ROSE at a tertiary center in Switzerland. Patients undergoing thyroid FNA from January 2016 to December 2019 were included. The primary outcome was the rate of nondiagnostic findings (Bethesda System for Reporting Thyroid Cytopathology category I).
In total, 410 thyroid nodule FNAs were performed. Of those, 309 with standard FNA and 101 with ROSE. The majority of patients were female (71%), with a median age of 56 years (IQR 46-68) and a nodule diameter of 1.9 cm (IQR 1.2-2.9). Implementation of ROSE led to a decrease in nondiagnostic findings from 41.1% to 23.8%, with an odds ratio of 0.42 (95% CI: 0.24-0.72; p = 0.002). Implementation of ROSE was associated with significantly higher rates of Bethesda category III (27.7% vs. 19.1%), category IV (15.8% vs. 5.5%), and Bethesda category VI (6.9% vs. 2.3%). Repeated FNA was performed in 29.1% before and 20.8% after implementation of ROSE (p = 0.18). The mean number of FNA per nodule was reduced from 1.4 (0.6) to 1.2 (0.4) with ROSE (p = 0.04).
Implementation of ROSE of thyroid nodule specimen improved diagnostic adequacy of FNA, reducing nondiagnostic findings. However, due to increased equivocal findings (Bethesda category III), there was no significant reduction of repeat FNA.
细针抽吸(FNA)已广泛应用于可疑甲状腺结节的评估。然而,仍有相当一部分结果为非诊断性的。快速现场评估(ROSE)的提出旨在提高 FNA 的整体充分性。
这是一项在瑞士一家三级中心进行的回顾性队列研究,比较了 ROSE 实施前后甲状腺 FNA 的充分性。研究纳入了 2016 年 1 月至 2019 年 12 月期间接受甲状腺 FNA 的患者。主要结局为非诊断性发现的比例(甲状腺细胞病理学报告的 Bethesda 系统分类 I 类)。
共进行了 410 例甲状腺结节 FNA,其中 309 例采用标准 FNA,101 例采用 ROSE。大多数患者为女性(71%),中位年龄为 56 岁(IQR 46-68),结节直径为 1.9cm(IQR 1.2-2.9)。ROSE 的实施使非诊断性发现的比例从 41.1%降至 23.8%,优势比为 0.42(95%CI:0.24-0.72;p=0.002)。ROSE 的实施与更高的 Bethesda 分类 III(27.7%比 19.1%)、IV(15.8%比 5.5%)和 VI(6.9%比 2.3%)的比例相关。在 ROSE 实施前,29.1%的患者需要重复 FNA,而实施后则为 20.8%(p=0.18)。实施 ROSE 后,每个结节的 FNA 次数从 1.4(0.6)减少至 1.2(0.4)(p=0.04)。
甲状腺结节标本 ROSE 的实施提高了 FNA 的诊断充分性,降低了非诊断性发现的比例。然而,由于可疑结果(Bethesda 分类 III)的增加,重复 FNA 的次数并没有显著减少。